Binah Capital Group Inc. (BCG)
CG Oncology Undervalued Going Into A Busy 2026
CG Oncology is positioned as a leading contender in high-risk BCG-unresponsive NMIBC, with its oncolytic adenovirus, cretostimogene grenadenorepvec (creto). Creto's efficacy and safety data rival JNJ's Inlexo, with a 75.5% any-time CR rate, similar 12mo/24mo CR rates, a longer response duration, and notably fewer Grade 3+ adverse events. CGON targets $2B peak revenue in its primary indication, with meaningful upside from intermediate-risk, BCG-naïve, and muscle-invasive bladder cancer opportunities.
1 Stock-Split AI Stock to Buy Before It Soars 450%, According to a Wall Street Expert
Philip Panaro is a founder and former CEO of Boston Consulting Group (BCG) Platinion, a division of BCG that offers technology consulting services. During an interview in November, Panaro told Schwab Network that Nvidia (NVDA -1.81%) could hit $800 per share by 2030 due to its leadership in artificial intelligence (AI) accelerators.
